viewEmyria Ltd

Emyria higher on entering data deal with Zelira to support Autism Spectrum Disorder trial

This deal leverages Emyria’s real-world data expertise and national network of clinics – Emerald Clinics - to facilitate patient access.

Emyria Ltd - Emyria enters data deal with Zelira Therapeutics to support Autism trial
This partnership highlights the value of Emyria’s clinical and real-world patient data to support treatment development for patients with unmet needs

Emyria Ltd (ASX:EMD) is trading higher after being selected to conduct an observational trial for patients diagnosed with Autism Spectrum Disorder (ASD) treated with Zelira Therapeutics (ASX:ZLD) HOPE™ range of products.

The trial, which will be one of the largest medicinal cannabis studies ever undertaken involving a specific range of products in patients diagnosed with ASD, has a study design that will facilitate strategic engagement with key stakeholders in the autism community and streamline patient access through Emyria’s national network of specialist medical clinics – Emerald Clinics.

These efforts will complement and augment the recent launch of HOPE™ in the Australian market.

The company's shares are trading 15% higher at 8.2 cents.

“Un-met clinical need”

Emyria managing director Dr Michael Winlo said: “We’re delighted to be working with Zelira Therapeutics again, this time to apply our real-world evidence data products and trial-ready clinical network to help progress the commercialisation and regulatory understanding of Zelira’s medicinal cannabis treatments in an area of unmet clinical need.

“Partnering with clinically-focused companies, such as Zelira, further supports our model of generating high-quality patient data to accelerate development of improved cannabis medicines for patients with unmet needs.”

Real-world longitudinal data

Under the terms of the agreement, Emyria will provide Zelira with real-world longitudinal data collected from ASD patients prescribed a HOPE™ product.

Data will include efficacy and safety insights relating to co-morbidities, concomitant medications, dosing information and patient responses to HOPE™ treatment as measured using standard ASD clinical and behavioural endpoints.

Zelira will pay Emyria fees of $115,000 over the first six months as well as a subscription fee for each patient enrolled in the study, up to a maximum of 150 participants.

The term of the agreement is for 12 months with an option to extend the subscription fees on an ongoing basis.

“One of largest observational studies undertaken”

Zelira managing director Richard Hopkins said: “We are excited to secure this agreement with Emyria to further augment our launch of HOPE™ in Australia, particularly after the successful launch of these products in the USA.

“This will be one of the largest observational medicinal cannabis studies ever undertaken in patients with ASD involving a specific range of products.

“This focused approach will generate very high-quality data that will complement our existing data-pack for HOPE™ and inform our global marketing strategy in real-time.

“The information will also inform the design of possible future clinical trials, reduce the risks and costs of development and accelerate the path to regulatory approval.”

Quick facts: Emyria Ltd

Price: 0.135 AUD

Market: ASX
Market Cap: $30.45 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Emyria Ltd named herein, including the promotion by the Company of Emyria Ltd in any Content on the Site, the Company receives from said issuer...


Emyria's Michael Winlo updates on new product launches

Emyria Ltd's (ASX:EMD) Michael Winlo talks Proactive's Andrew Scott through its product launch update for December. They're working on two treatments independently - one for mental health and the other for IBS. The company has identified that 60% of its patient and 4.8 million Australians are...

on 10/12/20

3 min read